Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3795-3800

  Tanimoto, Koichi ^a   Tomita, Haruyoshi ^a   Fujimoto, Shuhei ^a   Okuzumi, Katsuko ^b   Ike, Yasuyoshi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE AMPC; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; DORIPENEM; GENTAMICIN; MEROPENEM; METALLO BETA LACTAMASE; OFLOXACIN; PIPERACILLIN; PORIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; DNA SEQUENCE; DRUG POTENCY; GENE DELETION; GENE INSERTION; GENOTYPE; MEXAB GENE; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; OPRD GENE; OPRM GENE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA;

BASE SEQUENCE; BETA-LACTAM RESISTANCE; CARBAPENEMS; DNA PRIMERS; DNA, BACTERIAL; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 54049156512     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00464-08     Document Type: Article

References (33)

1. Brown, S., H. K. Young, and S. G. Amyes. 2005. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin. Microbiol. Infect. 11:15-23.
2. Bucaneve, G., A. Micozzi, F. Menichetti, P. Martino, M. S. Dionisi, G. Martinelli, B. Allione, D. D'Antonio, M. Buelli, A. M. Nosari, D. Cilloni, E. Zuffa, R. Cantaffa, G. Specchia, S. Amadori, F. Fabbiano, G. L. Deliliers, F. Lauria, R. Foa, and A. D. Favero. 2005. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N. Engl. J. Med. 353:977-987.
3. Büscher, K.-H., W. Cullmann, W. Dick, and W. Opferkuch. 1987. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob. Agents Chemother. 31:703-708.
4. Carratala, J., A. Fernandez-Sevilla, F. Tubau, M. Callis, and F. Gudiol. 1995. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin. Infect. Dis. 20:557-560.
5. Dumas, J. L., C. van Delden, K. Perron, and T. Köhler. 2006. Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol. Lett. 254:217-225.
6. Evans, K., L. Adewoye, and K. Poole. 2001. MexR repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa: identification of MexR binding sites in the mexA-mexR intergenic region. J. Bacteriol. 183:807-812.
7. Ge, Y., M. A. Wikler, D. F. Sahm, R. S. Blosser-Middleton, and J. A. Karlowsky. 2004. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. 48:1384-1396.
8. Iso, Y., T. Irie, T. Iwaki, M. Kii, Y. Sendo, K. Motokawa, and Y. Nishitani. 1996. Synthesis and modification of a novel 1 β-methyl carbapenem antibiotic, S-4661. J. Antibiot. 49:478-484.
9. Karp, J. E., W. G. Merz, C. Hendricksen, B. Laughon, T. Redden, B. J. Bamberger, J. G. Bartlett, R. Saral, and P. J. Burke. 1987. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann. Intern. Med. 106:1-7.
10. Kern, W. V., E. Andriof, M. Oethinger, P. Kern, J. Hacker, and R. Marre. 1994. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob. Agents Chemother. 38:681-687.
11. Köhler, T., M. Michea-Hamzehpour, S. F. Epp, and J.-C. Pechere. 1999. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. 43:424-427.
12. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680-685.
13. Li, X.-Z., D. Ma, D. M. Livermore, and H. Nikaido. 1994. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob. Agents Chemother. 38:1742-1752.
14. Livermore, D. M. 1992. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:2046-2048.
15. Livermore, D. M. 2001. Of Pseudomonas, porins, pumps, and carbapenems. J. Antimicrob. Chemother. 47:247-250.
16. Mamber, S. W., B. Kolek, K. W. Brookshire, D. P. Bonner, and J. Fung-Tomc. 1993. Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays. Antimicrob. Agents Chemother. 37:213-217.
17. Masuda, N., E. Sakagawa, and S. Ohya. 1995. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:645-649.
18. Miwa, H., Y. Kimura, Y. Jinushi, T. Fujimura, T. Nishikawa, T. Munekage, N. Kuroda, Y. Yamano, M. Tsuji, K. Okazaki, T. Sato, and H. Matsuda. 2005. Antipseudomonal activety of doripenem, a novel parenteral carbapenem antibiotic. Jpn. J. Chemother. 53(S-1):80-91.
19. Mushtaq, S., Y. Ge, and D. M. Livermore. 2004. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48:3086-3092.
20. Naas, T., L. Poirel, and P. Nordmann. 2006. Pyrosequencing for rapid identification of carbapenem-hydrolysing OXA-type β-lactamases in Acinetobacter baumannii. Clin. Microbiol. Infect. 12:1236-1240.
21. Nishio, H., M. Komatsu, N. Shibata, K. Shimakawa, N. Sueyoshi, T. Ura, K. Satoh, M. Toyokawa, T. Nakamura, Y. Wada, T. Orita, T. Kofuku, K. Yamasaki, M. Sakamoto, S. Kinoshita, M. Aihara, and Y. Arakawa. 2004. Metallo-β-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. J. Clin. Microbiol. 42:5256-5263.
22. Ozaki, S., M. Nagasawa, T. Sato, Y. Mure, and K. Inuzuka. 2007. Nation wide survey of bacterial drug susceptibilities of clinical isolates between 2004 and 2006 in Japan. In Y. Arakawa (ed.), Report of Research Project on Bacterial Drug Resistance. Japanese Ministry of Health Labor and Welfare, Tokyo, Japan.
23. Pai, H., J.-W. Kim, J. Kim, J. H. Lee, K. W. Choe, and N. Gotoh. 2001. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 45:480-484.
24. Quinn, J. P., E. J. Dudek, C. A. di Vincenzo, D. A. Lucks, and S. A. Lerner. 1986. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis. 154:289-294.
25. Sakyo, S., K. Tanimoto, S. Fujimoto, and Y. Ike. 1997. Carbapenem-induced resistance in Pseudomonas aeruginosa clinical strains to carbapenems including S4661, meropenem and imipenem, abstr. F-215, p. 183. Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother.
26. Sakyo, S., H. Tomita, K. Tanimoto, S. Fujimoto, and Y. Ike. 2006. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. J. Antibiot. 59:220-228.
27. Shimojima, M. 2007. Bacterial drug susceptibilities of clinical isolates between April 2006 and March 2007 in Japan. Med. Consult. New Remedies 43:697-753. (In Japanese.)
28. Somolinos, N., R. Arranz, M. C. Del Rey, and M. L. Jimenez. 1992. Super-infections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. J. Antimicrob. Chermother. 30:730-731.
29. Spratt, B. G. 1977. Properties of the penicillin-binding proteins of Escherichia coli K12. Eur. J. Biochem. 72:341-352.
30. Talbot, G. H., P. A. Cassileth, L. Paradiso, R. Correa-Coronas, L. Bond, and The Enoxacin Prophylaxis Study Group. 1993. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. Antimicrob. Agents Chemother. 37:474-482.
31. Tanaka, K., and H. Takahashi. 1991. Cloning and analysis of the gene (rpoDA) for the principal factor of Pseudomonas aeruginosa. Biochim. Biophys. Acta 1089:113-119.
32. Trias, J., J. Dufresne, R. C. Levesque, and H. Nikaido. 1989. Decreased outer membrane permeability in imipenem-resistant mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 33:1201-1206.
33. Trias, J., and H. Nikaido. 1990. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:52-57.